201 related articles for article (PubMed ID: 36941725)
21. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
[TBL] [Abstract][Full Text] [Related]
22. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Jeon MJ; Chun SM; Lee JY; Choi KW; Kim D; Kim TY; Jang SJ; Kim WB; Shong YK; Song DE; Kim WG
Endocrine; 2019 Apr; 64(1):130-138. PubMed ID: 30645724
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity-matched cohort study.
Yan L; Zhang M; Song Q; Xie F; Luo Y
Eur Radiol; 2022 Feb; 32(2):1216-1226. PubMed ID: 34357450
[TBL] [Abstract][Full Text] [Related]
24. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
Zhou YL; Zhang W; Gao EL; Dai XX; Yang H; Zhang XH; Wang OC
Asian Pac J Cancer Prev; 2012; 13(4):1267-72. PubMed ID: 22799316
[TBL] [Abstract][Full Text] [Related]
25. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.
Lin KL; Wang OC; Zhang XH; Dai XX; Hu XQ; Qu JM
Ann Surg Oncol; 2010 Dec; 17(12):3294-300. PubMed ID: 20953721
[TBL] [Abstract][Full Text] [Related]
26. Ultrasonography is valuable in evaluation of papillary thyroid microcarcinoma based on 5 mm tumor size.
Xia S; Dong Y; Kang H; Zhan W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S319-S323. PubMed ID: 29970683
[TBL] [Abstract][Full Text] [Related]
27. The analysis and validation of the prediction value of conventional and contrast-enhanced ultrasonography for
Li H; Ma J; Xi X; Tang J; Wang L; Wang L; Lin S; Zhang B
Gland Surg; 2022 Oct; 11(10):1683-1696. PubMed ID: 36353582
[TBL] [Abstract][Full Text] [Related]
28. Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases.
Zhi J; Zhao J; Gao M; Pan Y; Wu J; Li Y; Li D; Yu Y; Zheng X
Int J Clin Oncol; 2018 Feb; 23(1):59-65. PubMed ID: 28744725
[TBL] [Abstract][Full Text] [Related]
29. Peripheral location and infiltrative margin predict invasive features of papillary thyroid microcarcinoma.
Lee WK; Lee J; Kim H; Lee SG; Choi SH; Jeong S; Kwon HJ; Jung SG; Jo YS
Eur J Endocrinol; 2019 Aug; 181(2):139-149. PubMed ID: 31146263
[TBL] [Abstract][Full Text] [Related]
30. Papillary Thyroid Microcarcinoma: Reclassification to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): a Retrospective Clinicopathologic Study.
Shafique K; LiVolsi VA; Montone K; Baloch ZW
Endocr Pathol; 2018 Dec; 29(4):339-345. PubMed ID: 30196478
[TBL] [Abstract][Full Text] [Related]
31. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer.
Lin JD
Med Oncol; 2010 Jun; 27(2):510-8. PubMed ID: 19507072
[TBL] [Abstract][Full Text] [Related]
32. Incidental versus clinical diagnosis of papillary thyroid microcarcinoma. Long-term prognosis.
Ruiz J; Ríos A; Rodríguez JM; Paredes M; Soriano V; Oviedo MI; Hernández AM; Parrilla P
Endocrinol Diabetes Nutr (Engl Ed); 2020 May; 67(5):317-325. PubMed ID: 31882257
[TBL] [Abstract][Full Text] [Related]
33. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.
Roti E; Rossi R; Trasforini G; Bertelli F; Ambrosio MR; Busutti L; Pearce EN; Braverman LE; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2171-8. PubMed ID: 16478817
[TBL] [Abstract][Full Text] [Related]
34. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
35. Reconceptualize tall-cell variant papillary thyroid microcarcinoma: From a "sonographic histology" perspective.
Zhang Y; Mei F; He X; Ma J; Wang S
Front Endocrinol (Lausanne); 2022; 13():1001477. PubMed ID: 36425468
[TBL] [Abstract][Full Text] [Related]
36. Papillary thyroid microcarcinoma with minimal extrathyroidal extension. Is its course so indolent that it requires a less aggressive treatment?
Ruiz Pardo J; Ríos Zambudio A; Rodríguez González JM; Paredes Quiles M; Soriano Giménez V; Oviedo Ramírez MI; Hernández Martínez AM; Parrilla Paricio P
Rev Clin Esp (Barc); 2021 Mar; 221(3):131-138. PubMed ID: 33998460
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
Nucera C; Pontecorvi A
Front Endocrinol (Lausanne); 2012; 3():33. PubMed ID: 22649416
[TBL] [Abstract][Full Text] [Related]
38. Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma.
Song YS; Kang BH; Lee S; Yoo SK; Choi YS; Park J; Park DY; Lee KE; Seo JS; Park YJ
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32466217
[TBL] [Abstract][Full Text] [Related]
39. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
40. Washout DNA copy number analysis by low-coverage whole genome sequencing for assessment of thyroid FNAs.
Wu L; Zhou Y; Guan Y; Xiao R; Cai J; Chen W; Zheng M; Sun K; Chen C; Huang G; Zhang X; Zhai L; Qian Z; Shen SR
Front Endocrinol (Lausanne); 2022; 13():888072. PubMed ID: 36313748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
